TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is pleased to announce the formation of a U.S.-based subsidiary, Exo-Top Inc. (“Exo-Top”), that is expected to advance good manufacturing practice (“GMP”), fully characterized exosome production. The establishment of Exo-Top is a key step towards an independent and scalable supply of high-quality exosomes for the Company’s future nanodrug pipeline and collaboration opportunities following NurExone’s acquisition of a Master Cell Bank (“MCB”) of Mesenchymal Stem Cells (“MSC”).
Exosomes are increasingly recognized as a revolutionary drug delivery system with inherent therapeutic effects and capable of transporting therapeutic molecules – including ribonucleic acid, proteins, and small molecules – directly to target cells with high precision and minimal invasiveness.1 The exclusive MCB provides Exo-Top with a sustainable, cost-effective, and unique source of exosome-producing cells, a foundation for the production of fully characterized GMP-grade exosomes.